Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials
Chiu HY, Yeh TH, Huang YC, Chen PY
Pain physician · 54 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Taipei Medical University
- Subvenciones
- Taipei Medical University (TMU103-AE1-B11)
Según 1 financiador declarado.
Publicación
- Publicado
- 2016-01-14 · Pain Physician · vol. 1;19 · número 1;1 · págs. E97–E112
- Editorial
- American Society of Interventional Pain Physicians
- Citado
- 98 citas · más que el 78% de estudios similares · 1.5× el promedio de su campo
- Referencias
- 47 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Migraine and Headache Studies · Magnesium in Health and Disease · Traumatic Brain Injury and Neurovascular Disturbances
- Palabras clave
- Migraine, Medicine, Randomized controlled trial, Magnesium, Meta-analysis, Anesthesia, Randomization, Internal medicine
- MeSH
- humans, magnesium, treatment outcome, administration, oral, migraine disorders, randomized controlled trials as topic, administration, intravenous
1 autor
- Pin‐Yuan Chen🇹🇼 · autor de correspondenciaChang Gung University; Linkou Chang Gung Memorial Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Migraine attack has been associated with magnesium deficiency. Previous studies investigating the effect of intravenous and oral magnesium on acute migraine attacks and the prevention of migraine have produced equivocal findings.
Objective
To evaluate the effects of intravenous magnesium on acute migraine attacks and oral magnesium supplements on migraine prophylaxis.
Study design
A meta-analysis of randomized controlled trials (RCTs). Electronic databases, namely EMBASE, PubMed, the Wanfang Data Chinese Database, and the China Knowledge Resource Integrated Database were searched from inception to February 24, 2015.
Methods
This review was conducted according to the guidelines of the PRISMA. Only RCTs evaluating the effects of intravenous or oral magnesium on migraine compared with a control group were included.
Results
A total of 21 studies were included. Of which, 11 studies investigated the effects of intravenous magnesium on acute migraine (948 participants) and 10 examined the effects of oral magnesium on migraine prophylaxis (789 participants). Intravenous magnesium significantly relieved acute migraine within 15 - 45 minutes, 120 minutes, and 24 hours after the initial infusion (Odd ratios [ORs] = 0.23, 0.20, and 0.25, respectively). Oral magnesium significantly alleviated the frequency and intensity of migraine (ORs = 0.20 and 0.27).
Limitations
Some of the included studies did not adopt adequate randomization methods.
Conclusions
Intravenous magnesium reduces acute migraine attacks within 15 - 45 minutes, 120 minutes, and 24 hours after the initial infusion and oral magnesium alleviates the frequency and intensity of migraine. Intravenous and oral magnesium should be adapted as parts of multimodal approach to reduce migraine.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.